Evidence map›Paper›PMID 28757307›Full record

ArticleHeart rhythm2017

Association between oxidative stress and atrial fibrillation.

Ayman Samman Tahhan, Pratik B Sandesara, Salim S Hayek, Ayman Alkhoder, Kaavya Chivukula, Muhammad Hammadah, Heval Mohamed-Kelli, Wesley T O'Neal, Matthew Topel, Nima Ghasemzadeh and 8 more

Registry-linked trialAbstract readMulticenter Study
In one paragraph

Article in Heart rhythm, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04792190 (Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation), which is not on this map. Cited by 77 papers.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04792190 phase4completednot on this mapstarted 2021, after this paper: background citation

Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation (DAPA-AF) Prospective, Randomized, Multicenter, Placebo-Controlled Trial

TypeinterventionalSponsorUniversity of RochesterRan2021 to 2023Enrolled25ConditionsAtrial FibrillationArmsdapagliflozin, Placebo
3 · Its place in the literature

Who cites it

77 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Modifiable Risk Factors in Atrial Fibrillation: Clinical Implications and Pathophysiological Insights.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2026
    Review
  6. Article
  7. Article
  8. Pathogenesis of Oxidative Stress Biomarkers in Atrial Fibrillation: A Narrative Review.The Journal of innovations in cardiac rhythm management · 2026
    Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ayman Samman TahhanDivision of Cardiology, Emory University School of Medicine, Emory Clinical Cardiovascular Research Institute, Atlanta, Georgia.
Pratik B SandesaraDivision of Cardiology, Emory University School of Medicine, Emory Clinical Cardiovascular Research Institute, Atlanta, Georgia.
Salim S HayekDivision of Cardiology, Emory University School of Medicine, Emory Clinical Cardiovascular Research Institute, Atlanta, Georgia.
Ayman AlkhoderDivision of Cardiology, Emory University School of Medicine, Emory Clinical Cardiovascular Research Institute, Atlanta, Georgia.
Kaavya ChivukulaDivision of Cardiology, Emory University School of Medicine, Emory Clinical Cardiovascular Research Institute, Atlanta, Georgia.
Muhammad HammadahDivision of Cardiology, Emory University School of Medicine, Emory Clinical Cardiovascular Research Institute, Atlanta, Georgia.
Heval Mohamed-KelliDivision of Cardiology, Emory University School of Medicine, Emory Clinical Cardiovascular Research Institute, Atlanta, Georgia.
Wesley T O'NealDivision of Cardiology, Emory University School of Medicine, Emory Clinical Cardiovascular Research Institute, Atlanta, Georgia.
Matthew TopelDivision of Cardiology, Emory University School of Medicine, Emory Clinical Cardiovascular Research Institute, Atlanta, Georgia.
Nima GhasemzadehDivision of Cardiology, Emory University School of Medicine, Emory Clinical Cardiovascular Research Institute, Atlanta, Georgia.
Yi-An KoDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia.
Hiroshi AidaDivision of Cardiology, Emory University School of Medicine, Emory Clinical Cardiovascular Research Institute, Atlanta, Georgia.
Mazen GafeerDivision of Cardiology, Emory University School of Medicine, Emory Clinical Cardiovascular Research Institute, Atlanta, Georgia.
Laurence SperlingDivision of Cardiology, Emory University School of Medicine, Emory Clinical Cardiovascular Research Institute, Atlanta, Georgia.
Viola VaccarinoDivision of Cardiology, Emory University School of Medicine, Emory Clinical Cardiovascular Research Institute, Atlanta, Georgia; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia.
Yongliang LiangDivision of Pulmonary, Allergy and Critical Care Medicine, Clinical Biomarkers Laboratory, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.
Dean P JonesDivision of Pulmonary, Allergy and Critical Care Medicine, Clinical Biomarkers Laboratory, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.
Arshed A QuyyumiDivision of Cardiology, Emory University School of Medicine, Emory Clinical Cardiovascular Research Institute, Atlanta, Georgia. Electronic address: aquyyum@emory.edu.

Funding

Serious Hazards of Transfusion & Cellular Therapies: Mechanisms and InterventionP01HL086773 · NHLBI · EMORY UNIVERSITY · PI ROBACK, JOHN D · 2008 to 2019
$17.9M
Vascular Responses During Mental StressP01HL101398 · NHLBI · EMORY UNIVERSITY · PI QUYYUMI, ARSHED A · 2010 to 2015
$11.0M
Mental Stress and Myocardial Ischemia after MI: Sex Differences, Mechanisms and PrognosisR01HL109413 · NHLBI · EMORY UNIVERSITY · PI VACCARINO, VIOLA · 2012 to 2023
$6.9M
Multidisciplinary Research Training to Reduce Inequities in Cardiovascular HealthT32HL130025 · NHLBI · EMORY UNIVERSITY · PI Tené T Lewis, Viola Vaccarino · 2016 to 2026
$6.4M
Cell therapy for diabetic peripheral neurovascular complicationsDP3DK094346 · NIDDK · EMORY UNIVERSITY · PI CHENG, XIAODONG, YOON, YOUNG-SUP · 2011 to 2011
$6.1M
The role of the renin-angiotensin-endothelial pathway in ADRF1AG051633 · NIA · EMORY UNIVERSITY · PI HAJJAR, IHAB M, QUYYUMI, ARSHED A · 2015 to 2017
$6.0M
Adverse effects of RBC transfusions: A unifying hypothesisR01HL095479 · NHLBI · EMORY UNIVERSITY · PI ROBACK, JOHN D · 2009 to 2017
$5.2M
Mechanisms Linking Depression to Cardiovascular RiskR01HL068630 · NHLBI · EMORY UNIVERSITY · PI VACCARINO, VIOLA · 2001 to 2010
$4.8M
Metabolomics of subclinical and clinical cardiovascular diseaseP20HL113451 · NHLBI · EMORY UNIVERSITY · PI JONES, DEAN PAUL · 2012 to 2016
$4.3M
PTSD and Ischemic Heart Disease Progression: A Longitudinal Twin StudyR01HL125246 · NHLBI · EMORY UNIVERSITY · PI VACCARINO, VIOLA · 2015 to 2018
$3.4M
Posttraumatic Stress Disorder and Cardiovascular DiseaseR01AG026255 · NIA · EMORY UNIVERSITY · PI VACCARINO, VIOLA · 2004 to 2007
$2.8M
Heart Failure Clinical Trials NetworkU10HL110302 · NHLBI · EMORY UNIVERSITY · PI SMITH, ANDREW · 2012 to 2018
$2.5M
NHLBI NIH HHS F32 HL134290NHLBI NIH HHS K24 HL077506NHLBI NIH HHS P01 HL086773NHLBI NIH HHS P01 HL101398NHLBI NIH HHS P20 HL113451NHLBI NIH HHS R01 HL068630NHLBI NIH HHS R01 HL089650NHLBI NIH HHS R01 HL095479NHLBI NIH HHS R01 HL109413NHLBI NIH HHS R01 HL125246NHLBI NIH HHS R56 HL126558NHLBI NIH HHS T32 HL130025NHLBI NIH HHS U10 HL110302NIA NIH HHS R01 AG026255NIA NIH HHS RF1 AG051633NIDDK NIH HHS DP3 DK094346NINDS NIH HHS R01 NS064162
6 · The paper itself

Abstract

backgroundOxidative stress (OS) may be a key mechanism underlying the development of atrial fibrillation (AF) in experimental studies, but data in humans remain limited.

objectiveSystemic OS can be estimated by measurements of circulating levels of the aminothiols including glutathione, cysteine, and their oxidized products. We tested the hypothesis that the redox potentials of glutathione (E

methodsPlasma levels of aminothiols were measured in 1439 patients undergoing coronary angiography, of whom 148 (10.3%) had a diagnosis of AF. After a median follow-up of 6.3 years, 104 of 917 patients (11.5%) developed incident AF. Multivariate logistic regression and Cox regression models were used to determine whether OS markers were independent predictors of prevalent and incident AF after adjustment for traditional risk factors, heart failure, coronary artery disease, and high-sensitivity C-reactive protein level.

resultsFor each 10% increase in E

conclusionIncreased OS measured by the redox potentials of glutathione is associated with prevalent and incident AF. Therapies that modulate OS need to be investigated to treat and prevent AF.

Indexed as

Oxidative StressAdolescentAdultAgedAged, 80 and overAtrial FibrillationBiomarkersC-Reactive ProteinCysteineFollow-Up StudiesGeorgiaGlutathioneHumansMiddle AgedOdds RatioPrevalenceBiomarkersC-Reactive ProteinCysteineGlutathioneReactive Oxygen SpeciesAtrial fibrillationGlutathioneInflammationOxidative stressRedox potentials

Identifiers

PMID28757307
PMCPMC5817893

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.